Show simple item record

dc.contributor.authorMoore, Michael
dc.contributor.authorTaylor, G
dc.contributor.authorWhite, W J
dc.date.accessioned2011-03-22T17:14:16Z
dc.date.available2011-03-22T17:14:16Z
dc.date.issued1982
dc.identifier.citationSusceptibility of human leukaemias to cell-mediated cytotoxicity by interferon-treated allogeneic lymphocytes. 1982, 13 (1):56-61 Cancer Immunol Immunotheren
dc.identifier.issn0340-7004
dc.identifier.pmid6961951
dc.identifier.doi10.1007/BF00200202
dc.identifier.urihttp://hdl.handle.net/10541/125374
dc.description.abstractTwenty-two human leukaemias, comprising acute phase leucocytes from 13 acute myeloid and nine lymphoid leukaemias, were tested for susceptibility to spontaneous cell-mediated cytotoxicity (CMC) by untreated lymphocytes and lymphocytes treated for 18 h with 250 IU lymphoblastoid (Namalva) interferon (IFN-alpha). IFN-amplified killing (IAK) by lymphocytes from 24 normal lymphocyte donors was checked on the K562 erythroleukaemia cell line, for comparison with IAK on fresh leukaemias. Nine leukaemias were tested with lymphocytes from three donors, nine with lymphocytes from six donors, three with lymphocytes from nine donors, and one with lymphocytes from 11 donors. Some degree of susceptibility to IAK was found in five acute myeloid and five lymphoid leukaemias, which was markedly dependent upon the source of the effector lymphocytes and did not correlate with the degree of IAK on K562. The 12 other leukaemias were virtually resistant to IAK. The results emphasize the variability in the capacity of IFN-treated lymphocytes to lyse leukaemias that have not been adapted to tissue culture. The basis of effector recognition of cell line and fresh tumour targets is discussed.
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subjectAcute Myeloid Leukaemiaen
dc.subject.meshCell Line
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshInterferon Type I
dc.subject.meshLeukemia
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshLymphocytes
dc.titleSusceptibility of human leukaemias to cell-mediated cytotoxicity by interferon-treated allogeneic lymphocytes.en
dc.typeArticleen
dc.contributor.departmentPaterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX, UKen
dc.identifier.journalCancer Immunology, Immunotherapyen
html.description.abstractTwenty-two human leukaemias, comprising acute phase leucocytes from 13 acute myeloid and nine lymphoid leukaemias, were tested for susceptibility to spontaneous cell-mediated cytotoxicity (CMC) by untreated lymphocytes and lymphocytes treated for 18 h with 250 IU lymphoblastoid (Namalva) interferon (IFN-alpha). IFN-amplified killing (IAK) by lymphocytes from 24 normal lymphocyte donors was checked on the K562 erythroleukaemia cell line, for comparison with IAK on fresh leukaemias. Nine leukaemias were tested with lymphocytes from three donors, nine with lymphocytes from six donors, three with lymphocytes from nine donors, and one with lymphocytes from 11 donors. Some degree of susceptibility to IAK was found in five acute myeloid and five lymphoid leukaemias, which was markedly dependent upon the source of the effector lymphocytes and did not correlate with the degree of IAK on K562. The 12 other leukaemias were virtually resistant to IAK. The results emphasize the variability in the capacity of IFN-treated lymphocytes to lyse leukaemias that have not been adapted to tissue culture. The basis of effector recognition of cell line and fresh tumour targets is discussed.


This item appears in the following Collection(s)

Show simple item record